Anna Kaltenboeck: Untangling Drug Prices

Best of Health & Veritas, Summer 2023Подробнее

Historic Moment for Prescription Drugs, Anna Kaltenboeck, ATI AdvisoryПодробнее

PBM Reform and Additional Policy Impacts, Anna Kaltenboeck, ATI AdvisoryПодробнее

Untangling the High Cost of Prescription Drugs: A Deep Dive with BuzzRx’s Joseph KleimanПодробнее

Anna Kaltenboeck, Practice Director of Prescription Drug Reimbursement Practice at ATI Advisory, bioПодробнее

The IRA and Impacts on the Pharmaceutical Supply Chain, Anna Kaltenboeck, ATI AdvisoryПодробнее

Drug Prices and Innovation at FREOPP's Freedom & Progress Conference 2022Подробнее

How Will Medicare Negotiate Drug Prices? What Patients Need to KnowПодробнее

Bill pushes to lower prescription drug pricesПодробнее

The Covert Legal Strategy to Keep Your Drug Prices HighПодробнее

QuickTake: Taming U.S. Prescription Drug PricesПодробнее

U.S. Drug Prices: TakeawaysПодробнее

At COP29, a $300 billion a year climate finance deal sparks both outrage and hopeПодробнее

New law reduces prescription drug pricesПодробнее

Vt. economist says no simple fix to easing cost of prescription drugsПодробнее

Bill could cut prescription drug prices in half by allowing imports from CanadaПодробнее

Prescription Drug Inflation, Higher Healthcare CostsПодробнее